Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Phenergan 25mg/ml Solution for Injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Phenergan Injection is a clean, bright, colourless or almost colourless solution. |
Each ampoule contains 25mg/ml of the active substance Promethazine hydrochloride.
Also contains 0.5mg of sodium sulphite anhydrous (E221) and 0.7mg of sodium metabisulphite (E223).
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Promethazine |
Promethazine is a potent, long acting, antihistamine with additional anti-emetic central sedative and anti-cholinergic properties. |
| List of Excipients |
|---|
|
Sodium sulphite anhydrous (E221) |
Cardboard carton containing either 10 × 1 ml ampoules or 10 × 2 ml ampoules.
Not all pack sizes may be marketed.
Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
PL 04425/0648
Date of first authorisation: 16 March 1973
Date of latest renewal: 29 July 2002
| Drug | Countries | |
|---|---|---|
| PHENERGAN | France, Ireland, Israel, Malta, New Zealand, Tunisia, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
